

| | | | |
|-------------------------------|------------------------|---------------------|--|
| Notice of Allowability | Application No. | Applicant(s) | |
| | 10/715,129 | HU ET AL. | |
| | Examiner | Art Unit | |
| | Stuart F. Baum | 1638 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to papers filed 5/24/2006.
2. ☒ The allowed claim(s) is/are 1-21, 23, 25-26, 42-57 (renumbered 1-40).
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No./Mail Date <u>7/18/2006</u> . |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____. |


 Stuart F. Baum

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Patrick T. Skacel on 7/18/2006.

IN THE CLAIMS:

--10. (Currently Amended) A method of enhancing organ development in a plant, comprising:

transforming a plant cell with [at least one] a nucleotide sequence operably linked to a promoter that controls expression in a plant cell, wherein the nucleotide sequence is selected from the group consisting of:

- (a) a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1; and
- (b) a nucleic acid comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2; [and] cultivating the cell into a plant and expressing the nucleic acid sequence so that organ development is enhanced.--

--15. (Currently Amended) The method of claim [13] 14, wherein the leaf is a rosette leaf.--

Art Unit: 1638

--17. (Currently Amended) The method of claim 16, wherein the growth is enhanced by about 50% to about 120%, as compared to a wild-type plant.--

--19. (Currently Amended) The method of claim 10, wherein the enhanced development is a longer hypocotyl in a de-etiolated seedling of the plant, as compared to a wild-type plant.

20. (Currently Amended) The method of claim 10, wherein the enhanced development is delayed flowering, as compared to a wild-type plant.

21. (Currently Amended) The method of claim 10, wherein the enhanced development is an increase in seed number in a silique of the plant, as compared to a wild-type plant.--

--23. (Currently Amended) The method of claim 16, wherein the enhanced organ growth is a result of increased cell number, as compared to a wild-type plant.--

--42. (Currently Amended) A transformed plant cell having stably incorporated into its genome [at least one] a nucleotide sequence operably linked to a promoter that controls expression in a plant cell, wherein the nucleotide sequence is selected from the group consisting of:

- (a) a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1; and
- (b) a nucleic acid comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2.--

Art Unit: 1638

--45. (Currently Amended) A transgenic plant having stably incorporated into its genome [at least one] a nucleotide sequence operably linked to a promoter that controls expression in a plant cell, wherein the nucleotide sequence is selected from the group consisting of:

- (a) a nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1; and
- (b) a nucleic acid having a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2.--

--48. (Currently Amended) A transgenic seed of the plant of claim 45, wherein the seed comprises the [at least one] nucleotide sequence.

49. (Currently Amended) A method of regulating organ development in a plant, comprising transforming a plant cell with [at least one] a nucleotide sequence operably linked to a promoter that controls expression in a plant cell, wherein the nucleotide sequence is selected from the group consisting of:

- (a) a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:1; and
- (b) a nucleic acid comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:2;

cultivating the cell into a plant, whereby the nucleotide sequence is expressed and organ development is regulated.--

--55. (Currently Amended) The method of claim 49, wherein the regulated organ [growth] development is a result of altered cell division.--


Art Unit: 1638

--57. (Currently Amended) The method of claim 49, wherein the regulated organ [growth] development is a result of altered cell number.--

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart F. Baum whose telephone number is 571-272-0792. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached at 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

A handwritten signature in black ink, appearing to read "Stuart F. Baum".

Stuart F. Baum Ph.D.

Patent Examiner

Art Unit 1638

July 24, 2006

STUART F. BAUM, PH.D.
PATENT EXAMINER